Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Signs In-Network Contracts With Anthem Blue Cross, Blue Shield Plans

NEW YORK (GenomeWeb) – Sequenom said today that it has secured in-network contracts with Blue Cross and Blue Shield of Georgia, as well as Anthem Blue Cross and Blue Shield plans for Indiana, Kentucky, Missouri, Ohio, Wisconsin, and Virginia.

The agreements provide in-network coverage for Sequenom's noninvasive prenatal tests for high-risk and average-risk pregnancies. The Georgia agreement does not include HMO plans and the Virginia agreement does not include HealthKeepers products.

"Becoming an in-network provider with leading health insurers, particularly for average-risk pregnancies, is a critical component of our commercialization plan," Sequenom CEO and President Dirk van den Boom said in a statement.

The molecular diagnostic company originally inked a five-year agreement with the Blue Cross Blue Shield Association in 2013 to offer its testing services to the independent companies. However, the firm still had to negotiate in-network status with each of the 36 independent providers within the association.

In March, it signed agreements with Anthem Blue Cross and Blue Shield in Connecticut, Maine, and New Hampshire to provide coverage for NIPT for both high- and average-risk pregnancies.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.